Table 6.

Summary of outcomes

Outcome	Definition	Result
Overall survival	Survival after SRS/HFSRT	19.4 months (95% CI: 13.2–25.6 months)
Local control	Absence of new nodular contrast enhancement in the surgical bed compared with the baseline postoperative MRI.	1 year rate: 72% (95% CI: 60–83%)
Distant brain control	Absence of new, non-contiguous lesions in either MRI- or CT-follow-up. Leptomeningeal disease was rated as DBF.	1 year rate: 60% (95% CI: 49–72%),
Radiation necrosis	Determined based on histologic findings (after surgery) or magnetic resonance spectroscopy (MRS).	17 (22%)
Neurological death	Uncontrolled intracranial tumor progress or new/progressive neurological symptoms prior to death	16 (21%)
Time to any brain failure	Time after initial SRS/HFSRT to local failure or distant brain failure	13.9 months (95% CI: 10.7–17.1 months)
Symptom-free survival	Survival after initial SRS/HFSRT without new or progressive neurological symptoms	10.2 months (95% CI: 5.7–14.7 months)
WBRT-free survival	Survival after initial SRS/HFSRT without undergoing WBRT	17.7 months (95% CI: 13.2–22.3 months)
Deferment of WBRT	Postponing of WBRT (through regular MRI FU)	MRI FU at 3 months: p = 0.955 ≥1 MRI per 180 days: p = 0.268.
Time to salvage treatment	Time after initial SRS/HFSRT to first salvage treatment	15.7 months (range, 2.5–30.2 months)
Survival after salvage therapy	Survival after first salvage therapy	11.2 months (range, 0.3–33.7 months)

SRS stereotactic radiosurgery, HFSRT hypo-fractionated stereotactic radiotherapy, MRI magnetic resonance imaging, FU follow-up, CT computed tomography, DBF distant brain failure, MRS magnetic resonance spectroscopy, WBRT whole brain radiotherapy